Pfizer's RSV vaccine Abrysvo saw $375 million in sales in its first 5 months on the market and is seeing "very fast uptake," according to Pfizer's Chief Commercial Officer. Abrysvo is approved to prevent RSV in older adults and through maternal vaccination to protect infants. Declining sales of COVID treatments and vaccines like Paxlovid and Comirnaty caused Pfizer's overall third-quarter revenues to drop 41% to $13.2 billion, excluding COVID product sales were up 10%. Pfizer is exploring expanding into obesity treatment with its oral GLP-1 candidate danuglipron, with Phase 2b results expected before year-end. It aims to quickly move the candidate into Phase 3 trials.